

LOBBYING REPORT

Lobbying Disclosure Act of 1995 (Section 5) - **All Filers Are Required To Complete This Page**

1. Registrant Name:

ROYER & BABYAK

2. Address:

925 15TH ST NW 5TH FLOOR, WASHINGTON, DC 20005

3. Principal place of business (if different from line 2):

4. Contact Name: ROBERT S. ROYER

Telephone: 202-296-0784

E-mail (optional): rsroyer@royerandbabyak.com

Senate ID #: 33875-87

House ID #: 30734002

7. Client Name: ☐ Self

GENENTECH

TYPE OF REPORT

8. Year 2000 Midyear (January 1 - June 30): ☐ **OR** Year End (July 1 - December 31): ☒

9. Check if this filing amends a previously filed version of this report: ☐

10. Check if this is a Termination Report: ☐ => Termination Date: Jun 30, 2001 11. No Lobbying Activity: ☐

INCOME OR EXPENSES

Complete Either Line 12 **OR** Line 13

12. Lobbying Firms

INCOME relating to lobbying activities for this reporting period was:

Less than \$10,000: ☐

\$10,000 or more: ☒ => Income (nearest \$20,000): 40,000.00

Provide a good faith estimate, rounded to the nearest \$20,000, of all lobbying related income from the client (including all payments to the registrant by any other entity for lobbying activities on behalf of the client).

13. Organizations

EXPENSES relating to lobbying activities for this reporting period were:

Less than \$10,000: ☐

\$10,000 or more: ☐ => Expenses (nearest \$20,000): _____

14. Reporting Method.

Check box to indicate expense accounting method. See instructions for description of options.

- ☐ **Method A.** Reporting amounts using LDA definitions only
☐ **Method B.** Reporting amounts under section 6033(b)(8) of the Internal Revenue Code
☐ **Method C.** Reporting amounts under section 162(e) of the Internal Revenue Code

Registrant Name: ROYER & BABYAK Client Name: GENENTECH

LOBBYING ACTIVITY.

Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Attach additional page(s) as needed.

15. General issue area code: BUD (one per page)

16. Specific lobbying issues:

H.R. 4461 & S. 2536, Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, FY 2001, Title 6, provisions relating to the FDA Budget. H.R. 1167, Tribal Self-Governance Amendments of 1999, provisions relating to the availability of pharmaceutical products on the Federal Supply Schedule.

17. House(s) of Congress and Federal agencies contacted:

HOUSE OF REPRESENTATIVES

SENATE

18. Name of each individual who acted as a lobbyist in this issue area:

Name: BABYAK, GREGORY R.

Covered Official Position (if applicable): N/A

19. Interest of each foreign entity in the specific issues listed on line 16 above. **None**

LOBBYING ACTIVITY.

Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Attach additional page(s) as needed.

15. General issue area code: CPT (one per page)

16. Specific lobbying issues:

No specific legislation -- issues relating to patentability of gene-related inventions. S. 2536 & H.R. 4461, Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act for FY 2001; H.R. 3908, the 2000 Emergency Supplemental Appropriations Act; H.R. 4690 and H.R. 4942, the Commerce, Justice, State and Judiciary Appropriations act for FY 2001; and S. 2553 and H.R. 4577, the Labor, Health and Human Services, and Education Appropriations Act for FY 2001 -- all provisions dealing with process patent term extensions.

17. House(s) of Congress and Federal agencies contacted:

HOUSE OF REPRESENTATIVES
SENATE

18. Name of each individual who acted as a lobbyist in this issue area:

Name: BABYAK, GREGORY R.

Covered Official Position (if applicable): N/A

19. Interest of each foreign entity in the specific issues listed on line 16 above. **None**

LOBBYING ACTIVITY.

Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Attach additional page(s) as needed.

15. General issue area code: HCR (one per page)

16. Specific lobbying issues:

S. 578, Health Care Personal Information Nondisclosure Act of 1999; S. 573, Medical Information Privacy and Security Act; S. 881, Medical Information Protection Act of 1999; H.R. 2470, Medical Information and Research Enhancement Act -- all provisions as they relate to medical confidentiality. S. 543 & H.R. 306, Genetic Information Nondiscrimination in Health Insurance Act of 1999, all provisions as they relate to genetic information.

17. House(s) of Congress and Federal agencies contacted:

HOUSE OF REPRESENTATIVES

SENATE

18. Name of each individual who acted as a lobbyist in this issue area:

Name: BABYAK, GREGORY R.

Covered Official Position (if applicable): N/A

19. Interest of each foreign entity in the specific issues listed on line 16 above. **None**

Registrant Name: ROYER & BABYAK Client Name: GENENTECH

LOBBYING ACTIVITY.

Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Attach additional page(s) as needed.

15. General issue area code: MMM (one per page)

16. Specific lobbying issues:

H.R. 664 & S. 731, The Prescription Drug Fairness for Seniors Act of 1999; S. 841 & H.R. 1495, Access to Rx Medications in the Medicare Act of 1999; H.R. 4607, the Medicare Prescription Drug Act of 2000; S. 1895, the Medicare Preservation and Improvement Act; S. 1480, the Seniors Prescription Insurance Coverage Equity Act -- all provisions as they relate to the creation of a medicare drug benefit.

17. House(s) of Congress and Federal agencies contacted:

HOUSE OF REPRESENTATIVES

SENATE

18. Name of each individual who acted as a lobbyist in this issue area:

Name: BABYAK, GREGORY R.

Covered Official Position (if applicable): N/A

19. Interest of each foreign entity in the specific issues listed on line 16 above. **None**

LOBBYING ACTIVITY.

Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Attach additional page(s) as needed.

15. General issue area code: SCI (one per page)

16. Specific lobbying issues:

S. 296, the Federal Research Investment Act, all provisions as they relate to federal research investment.

17. House(s) of Congress and Federal agencies contacted:

HOUSE OF REPRESENTATIVES

SENATE

18. Name of each individual who acted as a lobbyist in this issue area:

Name: BABYAK, GREGORY R.

Covered Official Position (if applicable): N/A

19. Interest of each foreign entity in the specific issues listed on line 16 above. **None**

Registrant Name: ROYER & BABYAK Client Name: GENENTECH

LOBBYING ACTIVITY.

Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Attach additional page(s) as needed.

15. General issue area code: TAX (one per page)

16. Specific lobbying issues:

S. 1010 & H.R. 1039, "Medical Innovation Tax Credit," all provisions as they relate to the medical innovation tax credit.

17. House(s) of Congress and Federal agencies contacted:

HOUSE OF REPRESENTATIVES

SENATE

18. Name of each individual who acted as a lobbyist in this issue area:

Name: BABYAK, GREGORY R.

Covered Official Position (if applicable): N/A

19. Interest of each foreign entity in the specific issues listed on line 16 above. **None**

Signature: ON FILE Date: Feb 14, 2001

Printed Name and Title: GREGORY R. BABYAK - PARTNER